Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)
Hong Kong
· Delayed Price · Currency is HKD 0.9400
+0.0100 (1.08%)
May 7, 2025, 3:38 PM HKT
HKG:3737 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2,215 | 2,050 | 1,826 | 1,747 | 1,604 | Upgrade
|
| Revenue Growth (YoY) | 8.05% | 12.26% | 4.55% | 8.89% | 19.50% | Upgrade
|
| Cost of Revenue | 933.45 | 835.21 | 758.59 | 685.15 | 612.79 | Upgrade
|
| Gross Profit | 1,281 | 1,215 | 1,067 | 1,061 | 991.09 | Upgrade
|
| Selling, General & Admin | 1,094 | 994.81 | 914.57 | 932.14 | 790.58 | Upgrade
|
| Other Operating Expenses | 61.72 | 55.4 | 49.28 | 49.64 | 59.4 | Upgrade
|
| Operating Expenses | 1,156 | 1,050 | 963.84 | 981.77 | 849.97 | Upgrade
|
| Operating Income | 125.14 | 164.4 | 103.51 | 79.58 | 141.12 | Upgrade
|
| Interest Expense | -6.99 | -7.87 | -6.56 | -7.08 | -5.22 | Upgrade
|
| Interest & Investment Income | 5.2 | 7.02 | 4 | 4.22 | 10.08 | Upgrade
|
| Other Non Operating Income (Expenses) | 32.76 | 40.19 | 26.58 | 24.6 | 13.65 | Upgrade
|
| EBT Excluding Unusual Items | 156.1 | 203.74 | 127.53 | 101.32 | 159.63 | Upgrade
|
| Gain (Loss) on Sale of Investments | -9.75 | 3.41 | 2.43 | -39.61 | 7.81 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.55 | 0.43 | 0.69 | 0.11 | -0.22 | Upgrade
|
| Pretax Income | 146.9 | 207.58 | 130.65 | 61.81 | 167.22 | Upgrade
|
| Income Tax Expense | 50.75 | 43.45 | 23.74 | 9.45 | 28.6 | Upgrade
|
| Earnings From Continuing Operations | 96.15 | 164.13 | 106.92 | 52.37 | 138.62 | Upgrade
|
| Minority Interest in Earnings | -0.94 | -1.36 | -0.53 | -0.24 | -0.09 | Upgrade
|
| Net Income | 95.21 | 162.78 | 106.39 | 52.13 | 138.53 | Upgrade
|
| Net Income to Common | 95.21 | 162.78 | 106.39 | 52.13 | 138.53 | Upgrade
|
| Net Income Growth | -41.51% | 53.00% | 104.09% | -62.37% | 20.78% | Upgrade
|
| Shares Outstanding (Basic) | 845 | 847 | 847 | 837 | 829 | Upgrade
|
| Shares Outstanding (Diluted) | 845 | 847 | 847 | 837 | 829 | Upgrade
|
| Shares Change (YoY) | -0.18% | - | 1.20% | 0.98% | -0.69% | Upgrade
|
| EPS (Basic) | 0.11 | 0.19 | 0.13 | 0.06 | 0.17 | Upgrade
|
| EPS (Diluted) | 0.11 | 0.19 | 0.13 | 0.06 | 0.17 | Upgrade
|
| EPS Growth | -42.11% | 51.27% | 109.34% | -64.10% | 21.45% | Upgrade
|
| Free Cash Flow | 40.72 | -67.68 | 196.17 | -7.47 | -20.81 | Upgrade
|
| Free Cash Flow Per Share | 0.05 | -0.08 | 0.23 | -0.01 | -0.03 | Upgrade
|
| Dividend Per Share | 0.047 | 0.082 | 0.053 | - | 0.031 | Upgrade
|
| Dividend Growth | -42.49% | 53.92% | - | - | -42.39% | Upgrade
|
| Gross Margin | 57.85% | 59.25% | 58.45% | 60.77% | 61.79% | Upgrade
|
| Operating Margin | 5.65% | 8.02% | 5.67% | 4.56% | 8.80% | Upgrade
|
| Profit Margin | 4.30% | 7.94% | 5.83% | 2.99% | 8.64% | Upgrade
|
| Free Cash Flow Margin | 1.84% | -3.30% | 10.74% | -0.43% | -1.30% | Upgrade
|
| EBITDA | 172.32 | 215.3 | 153.87 | 119.71 | 203.69 | Upgrade
|
| EBITDA Margin | 7.78% | 10.50% | 8.43% | 6.85% | 12.70% | Upgrade
|
| D&A For EBITDA | 47.19 | 50.9 | 50.37 | 40.14 | 62.58 | Upgrade
|
| EBIT | 125.14 | 164.4 | 103.51 | 79.58 | 141.12 | Upgrade
|
| EBIT Margin | 5.65% | 8.02% | 5.67% | 4.56% | 8.80% | Upgrade
|
| Effective Tax Rate | 34.55% | 20.93% | 18.17% | 15.28% | 17.11% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.